Source: Eur Respir Rev 2014; 23: 92-105
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Sebastian, Martin and Schmittel, Alexander and Reck, Martin. First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology. Eur Respir Rev 2014; 23: 92-105

Member's Comments

No comment yet.

Related content which might interest you: Radiation therapy for augmenting the efficacy of immunotherapy in advanced non-small cell lung cancer: a case-controlled study Source: ERJ Open Res, 6 (1) 00189-2019; 10.1183/23120541.00189-2019 Year: 2020 Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study Source: International Congress 2018 – Lung cancer: personalised medicine Year: 2018 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2012; 39: 172-179 Year: 2012 Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3 Source: Eur Respir J 2011; 39: 172-179 Year: 2012 Our experience with crizotinib in the treatment of non-small cell lung cancer Source: Virtual Congress 2020 – Prognostic and predictive factors: treatment of lung cancer Year: 2020 Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives Source: Eur Respir Rev 2011; 20: 45-52 Year: 2011 Second-line medical treatment for nonsmall cell lung cancer: what the studies say Source: Annual Congress 2010 - Lung cancer progress after first-line therapy: which treatment makes sense and which does not? Year: 2010 Radiotherapy in the treatment of nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 207–243 Year: 2009 Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study Source: Eur Respir J, 52 (4) 1800884; 10.1183/13993003.00884-2018 Year: 2018 Second-line therapy in elderly patients with advanced nonsmall cell lung cancer Source: Eur Respir J 2014; 43: 240-249 Year: 2004 First- and second-line therapy for advanced nonsmall cell lung cancer Source: Eur Respir J 2009; 33: 915-930 Year: 2009 The method of individualisation of treatment and prognosis for advanced non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Implementation study: role of docetaxel after a first line cisplatinum based chemotherapy for non-small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Chemotherapy in advanced nonsmall cell lung cancer Source: Eur Respir Mon; 2009: 44: 271–283 Year: 2009 Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 376s Year: 2001 Use of 2nd-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Chemotherapy with oral vinorelbine for geriatric patients with advanced non-small cell lung cancer – preliminary results Source: Eur Respir J 2006; 28: Suppl. 50, 752s Year: 2006 Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study Source: Eur Respir J 2007; 29: 128-133 Year: 2007 Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012 Second line therapy for advanced non-small cell lung cancer Source: European Multidisciplinary Conference in Thoracic Oncology 2009 Year: 2009